The multicentre, double-blind, sham-controlled RELIEVE-HF trial (NCT03499236) explored inter-atrial shunt treatment for patients with HF and either reduced or preserved EF [1]. The randomised 508 participants to receive a V-Wave® Ventura® shunt or a placebo procedure. To enable differentiation of results according to EF, randomisation was stratified according to reduced (≤40%) and preserved EF (>40%).
The effectiveness up to 2 years was assessed by a hierarchical composite of all-cause death, heart transplant or left ventricular assist device (LVAD), recurrent HF hospitalisations, out-patient worsening HF events, and change in Kansas City Cardiomyopathy Questionnaire overall summary scores (KCCQ-OSS). The results on each level were reported in wins and losses for the trial arms.
RELIEVE-HF did not meet this primary endpoint as no significant difference was found for the win ratio between groups (P=0.20). Similar results were found for the risk of all cardiovascular (CV) events and KCCQ-OSS. “Where the results became particularly informative, is when we looked at the stratified randomisations according to ejection fraction,” Prof. Gregg Stone (Icahn School of Medicine at Mount Sinai, New York, USA) highlighted.
In patients with LVEF≤40%, the shunt led to a CV event rate of 49% per year compared with 88.6% in the placebo group (relative rate ratio 0.55; 95%CI 0.42–0.73; P<0.0001). “In patients with preserved EF the exact opposite pattern was seen,” revealed Prof. Stone. Their control-arm event rate was 35.9%, while 60.2% in the shunt group (relative rate ratio 1.68; 95%CI 1.29–2.19; P=0.0001). The risk of all CV events painted a similar picture of benefit and harm at stratification. Of note, the change in quality-of-life did not differ between the strata, pointing to a relevant placebo effect in KCCQ-OSS outcomes.
- Stone G. A double-blind, randomized placebo procedure-controlled trial of an interatrial shunt in patients with HfrEF and HfpEF: principal results from the RELIEVE-HF trial. LB1, Session 402, ACC 2024 Scientific Session, 6–8 April, Atlanta, USA.
Medical writing support was provided by Karin Drooff, MPH.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« BE ACTIVE shows that small incentives increase daily steps in high-risk patients Next Article
STEP-HFpEF DM: Semaglutide beneficial in patients with HFpEF and diabetes »
« BE ACTIVE shows that small incentives increase daily steps in high-risk patients Next Article
STEP-HFpEF DM: Semaglutide beneficial in patients with HFpEF and diabetes »
Table of Contents: ACC 2024
Featured articles
Matters of the heart: late-breaking news from the American College of Cardiology
KARDIA-2: Add-on zilebesiran effectively lowers blood pressure
STEP-HFpEF DM: Semaglutide beneficial in patients with HFpEF and diabetes
Online First
IVUS-guided PCI beats angiography in patients with acute coronary syndrome
To stent or not to stent? Favourable results for preventive PCI in vulnerable atherosclerotic plaques
Peripheral artery disease: procedure-guidance by IVUS superior to angiography
SGLT2 inhibition in heart failure more advantageous for women than men
Microaxial flow pump safes lives but comes with a price tag
KARDIA-2: Add-on zilebesiran effectively lowers blood pressure
Safety of TAVI non-inferior to SAVR in patients with lower surgical risk
New PCSK9 inhibitor achieves LDL-C goals in high-risk and very high-risk patients
Protein drinks and exercise intervention improve physical performance in frail patients undergoing TAVR
AEGIS-II: Negative primary endpoint but infusions might benefit subgroups of patients
STEP-HFpEF DM: Semaglutide beneficial in patients with HFpEF and diabetes
RELIEVE-HF: Inter-atrial shunt might be advantageous in HFrEF
BE ACTIVE shows that small incentives increase daily steps in high-risk patients
“Inclisiran first” strategy highly effective regarding LDL control in ASCVD
Olezarsen highly effective in lowering triglycerides
Related Articles
April 18, 2024
Skin cancer in transplant patients: practical challenges
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy